Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 29;14(4):e070801.
doi: 10.1136/bmjopen-2022-070801.

Effect of vitamin D in addition to letrozole on the ovulation rate of women with polycystic ovary syndrome: protocol of a multicentre randomised double-blind controlled trial

Jennifer K Y Ko  1 , Sofie S F Yung  1 , Shui Fan Lai  2 , Rebecca S F Wan  3 , Catherine K Y Wong  4 , Keedon Wong  5 , Ching-Lung Cheung  6 , Ernest H Y Ng  1 , Raymond H W Li  7
Affiliations

Effect of vitamin D in addition to letrozole on the ovulation rate of women with polycystic ovary syndrome: protocol of a multicentre randomised double-blind controlled trial

Jennifer K Y Ko et al. BMJ Open. .

Abstract

Introduction: Low vitamin D status is prevalent among women with polycystic ovary syndrome (PCOS). The objective of the study is to assess the effect of vitamin D supplementation on (1) the ovulation rate to letrozole and (2) other reproductive, endocrine and metabolic outcomes after 1 year of supplementation in women with PCOS.

Methods and analysis: This is a multicentre, randomised, double-blind, controlled clinical trial. A total of 220 anovulatory women with PCOS diagnosed by the Rotterdam criteria will be recruited. They will be randomly assigned to either the (1) vitamin D supplementation group or (2) placebo group. Those in the vitamin D group will take oral Vitamin D3 50 000 IU/week for 4 weeks, followed by 50 000 IU once every 2 weeks for 52 weeks. Those who remain anovulatory after 6 months will be treated with a 6-month course of letrozole (2.5 mg to 7.5 mg for 5 days per cycle titrated according to response) for ovulation induction. The primary outcome is the ovulation rate. All statistical analyses will be performed using intention-to-treat and per protocol analyses.

Ethics and dissemination: Ethics approval was sought from the Institutional Review Board of the participating units. All participants will provide written informed consent before joining the study. The results of the study will be submitted to scientific conferences and peer-reviewed journals.

Trial registration number: NCT04650880.

Keywords: GYNAECOLOGY; General endocrinology; REPRODUCTIVE MEDICINE.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Schedule of enrolment, interventions and assessments.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lerchbaum E, Obermayer-Pietsch B. Vitamin D and fertility: a systematic review. Eur J Endocrinol 2012;166:765–78. 10.1530/EJE-11-0984 - DOI - PubMed
    1. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. . Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911–30. 10.1210/jc.2011-0385 - DOI - PubMed
    1. Palacios C, Gonzalez L. Is vitamin D deficiency a major global public health problem. J Steroid Biochem Mol Biol 2014;144 Pt A:138–45. 10.1016/j.jsbmb.2013.11.003 - DOI - PMC - PubMed
    1. Teede HJ, Misso ML, Costello MF, et al. . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 2018;33:1602–18. 10.1093/humrep/dey256 - DOI - PMC - PubMed
    1. Li HWR, Brereton RE, Anderson RA, et al. . Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011;60:1475–81. 10.1016/j.metabol.2011.03.002 - DOI - PubMed

Publication types

MeSH terms

Associated data